Preventing Asthma in High Risk Kids (PARK)
A double blinded four year study for children 24 - 47 months with the goal of identifying if injections of Omalizumab (Xolair) for two years, could prevent children from getting Asthma and lessen the severety of their breathing problems as they grow.
Study phase: II
Basic eligibility criteria:
Please contact the study coordinator for additional eligibility information.
24-47 months old.
Have had 2-4 wheezing episodes in the past 12 months.
Primary disease category: Asthma & Lung
This study is enrolling healthy volunteers.
Sponsor: The National Institute of Allergy and Infectious Diseases (NIAID)
Protocol number: IRB-P00019640
Projected enrollment dates: September 2019 to November 2023
Official study title: Preventing Asthma in High Risk Kids (PARK)